المؤلفون: Huang J; Department of Urology, Minhang Hospital, Fudan University, Shanghai, China., Leng F; Department of Critical Care Medicine, Zhongshan Hospital, Fudan University, Shanghai 200032, China. Electronic address: leng.fei@zs-hospital.sh.cn.

المصدر: The Lancet. Oncology [Lancet Oncol] 2024 Jul; Vol. 25 (7), pp. e283.

نوع المنشور: News; Letter

بيانات الدورية: Publisher: Lancet Pub. Group Country of Publication: England NLM ID: 100957246 Publication Model: Print Cited Medium: Internet ISSN: 1474-5488 (Electronic) Linking ISSN: 14702045 NLM ISO Abbreviation: Lancet Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Prostatic Neoplasms, Castration-Resistant*/drug therapy , Prostatic Neoplasms, Castration-Resistant*/pathology , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use, Humans ; Male ; Androgen Antagonists/therapeutic use ; Neoplasm Metastasis ; Treatment Outcome ; Androgen Receptor Antagonists/therapeutic use

المؤلفون: Rescigno P; The Institute of Cancer Research, London, UK; The Royal Marsden NHS Foundation Trust, London, UK; Newcastle University, Newcastle upon Tyne, UK., Porta N; The Institute of Cancer Research, London, UK., Finneran L; The Institute of Cancer Research, London, UK., Riisnaes R; The Institute of Cancer Research, London, UK., Figueiredo I; The Institute of Cancer Research, London, UK., Carreira S; The Institute of Cancer Research, London, UK., Flohr P; The Institute of Cancer Research, London, UK., Miranda S; The Institute of Cancer Research, London, UK., Bertan C; The Institute of Cancer Research, London, UK., Ferreira A; The Institute of Cancer Research, London, UK., Crespo M; The Institute of Cancer Research, London, UK., Rodrigues DN; The Institute of Cancer Research, London, UK., Gurel B; The Institute of Cancer Research, London, UK., Nobes J; Norfolk & Norwich Hospital, Norwich, UK., Crabb S; University Hospital Southampton NHS Foundation Trust, Southampton, UK., Malik Z; The Clatterbridge Cancer Centre, Liverpool, UK., Ralph C; St James's University Hospital, Leeds, UK., McGovern U; University College Hospital, London, UK., Hoskin P; Mount Vernon Cancer Centre, Northwood, UK., Jones RJ; University of Glasgow, Beatson West of Scotland Cancer Centre, Glasgow, UK., Birtle A; Rosemere Cancer Centre, Lancashire Teaching Hospitals, Preston, UK; University of Manchester, Manchester, UK; University of Central Lancashire, Preston, UK., Gale J; Queen Alexandra Hospital, Portsmouth, UK., Sankey P; University Hospitals Plymouth, Plymouth, UK., Jain S; Queen's University Belfast, Belfast, UK., McLaren D; Western General Hospital, Edinburgh, UK., Chadwick E; Nottingham City Hospital, Nottingham, UK., Espinasse A; The Institute of Cancer Research, London, UK., Hall E; The Institute of Cancer Research, London, UK., de Bono J; The Institute of Cancer Research, London, UK; The Royal Marsden NHS Foundation Trust, London, UK. Electronic address: johann.de-bono@icr.ac.uk.

المصدر: European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2024 Jul; Vol. 205, pp. 114103. Date of Electronic Publication: 2024 May 08.

نوع المنشور: Journal Article; Clinical Trial, Phase II; Randomized Controlled Trial; Multicenter Study

بيانات الدورية: Publisher: Elsevier Science Ltd Country of Publication: England NLM ID: 9005373 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0852 (Electronic) Linking ISSN: 09598049 NLM ISO Abbreviation: Eur J Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Prostatic Neoplasms, Castration-Resistant*/drug therapy , Prostatic Neoplasms, Castration-Resistant*/pathology , Phenylthiohydantoin*/administration & dosage , Phenylthiohydantoin*/therapeutic use , Phenylthiohydantoin*/adverse effects , Benzamides* , Docetaxel*/administration & dosage , Docetaxel*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/adverse effects , Nitriles* , Pyrimidines*/therapeutic use , Pyrimidines*/administration & dosage , Pyrimidines*/adverse effects, Humans ; Male ; Aged ; Middle Aged ; Double-Blind Method ; Androstenes/therapeutic use ; Androstenes/administration & dosage ; Aged, 80 and over ; Pyrroles

المؤلفون: Desai KB; Section of Hematology/Oncology, University of Chicago, Chicago, Illinois., Serritella AV; Section of Hematology/Oncology, Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois., Stadler WM; Section of Hematology/Oncology, University of Chicago, Chicago, Illinois., O'Donnell PH; Section of Hematology/Oncology, University of Chicago, Chicago, Illinois., Sweis RF; Section of Hematology/Oncology, University of Chicago, Chicago, Illinois., Szmulewitz RZ; Section of Hematology/Oncology, University of Chicago, Chicago, Illinois.

المصدر: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2024 Jun 03; Vol. 30 (11), pp. 2384-2392.

نوع المنشور: Journal Article; Clinical Trial, Phase I

بيانات الدورية: Publisher: The Association Country of Publication: United States NLM ID: 9502500 Publication Model: Print Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE

مواضيع طبية MeSH: Phenylthiohydantoin*/administration & dosage , Phenylthiohydantoin*/adverse effects , Phenylthiohydantoin*/therapeutic use , Phenylthiohydantoin*/pharmacokinetics , Benzamides*/administration & dosage , Prostatic Neoplasms, Castration-Resistant*/drug therapy , Prostatic Neoplasms, Castration-Resistant*/pathology , Nitriles*/administration & dosage , Receptors, Glucocorticoid* , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/adverse effects, Humans ; Male ; Aged ; Middle Aged ; Aged, 80 and over ; Neoplasm Metastasis ; Androgen Receptor Antagonists/therapeutic use ; Androgen Receptor Antagonists/administration & dosage ; Androgen Receptor Antagonists/pharmacokinetics ; Androgen Receptor Antagonists/adverse effects ; Receptors, Androgen/metabolism ; Treatment Outcome

المؤلفون: Alonso-Gordoa T; Hospital Universitario Ramón y Cajal, Madrid, Spain. Electronic address: talonso@salud.madrid.org., Goodman M; Atrium Health Wake Forest Baptist, Winston-Salem, USA., Vulsteke C; Integrated Cancer Center, Maria Middelares General Hospital, Ghent; Center for Oncological Research, University of Antwerp, Antwerp, Belgium., Roubaud G; Institut Bergonié, Bordeaux, France., Zhang J; H. Lee Moffitt Cancer Center & Research Institute, Tampa., Parikh M; Hematology/Oncology Clinic, UC Davis Comprehensive Cancer Center, Sacramento, USA., Piulats JM; Catalan Institute of Oncology, Barcelona, Spain., Azaro A; Oncology R&D, AstraZeneca, Cambridge., James GD; Medical Statistics Consultancy Ltd, London, UK., Cavazzina R; Oncology R&D, AstraZeneca, Cambridge., Gangl ET; BioPharma R&D, AstraZeneca, Boston., Thompson J; Oncology R&D, AstraZeneca, Cambridge., Pouliot G; Oncology R&D, AstraZeneca, Waltham., Kumar R; Oncology R&D, AstraZeneca, Gaithersburg., Sweeney C; Dana-Farber Cancer Institute, Boston, USA.

المصدر: ESMO open [ESMO Open] 2024 Jun; Vol. 9 (6), pp. 103446. Date of Electronic Publication: 2024 Jun 04.

نوع المنشور: Journal Article; Clinical Trial, Phase II; Multicenter Study

بيانات الدورية: Publisher: Elsevier Country of Publication: England NLM ID: 101690685 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2059-7029 (Electronic) Linking ISSN: 20597029 NLM ISO Abbreviation: ESMO Open Subsets: MEDLINE

مواضيع طبية MeSH: Prostatic Neoplasms, Castration-Resistant*/drug therapy , Prostatic Neoplasms, Castration-Resistant*/pathology , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/pharmacology , Antibodies, Monoclonal*/therapeutic use , Antibodies, Monoclonal*/pharmacology , Antibodies, Monoclonal*/administration & dosage, Humans ; Male ; Aged ; Middle Aged ; Taxoids/therapeutic use ; Taxoids/pharmacology ; Taxoids/administration & dosage ; Aged, 80 and over ; Progression-Free Survival ; Neoplasm Metastasis

المؤلفون: Yu EY; Division of Hematology and Oncology, Fred Hutchinson Cancer Center and University of Washington, Seattle, WA, USA. Electronic address: evanyu@u.washington.edu., Berry WR; Duke Cancer Center Cary, Cary, NC, USA., Gurney H; Department of Clinical Medicine, Macquarie University, Sydney, Australia., Retz M; University Hospital Rechts der Isar, Technical University of Munich, Munich, Germany., Conter HJ; University of Western Ontario, Brampton, Canada., Laguerre B; Center Eugène Marquis, Rennes, France., Fong PCC; Aukland City Hospital and the University of Aukland., Ferrario C; Jewish General Hospital, Montreal, Canada., Todenhöfer T; Studienpraxis Urologie, Nürtingen, Germany., Gravis G; Institut Paoli-Calmettes, Marseille, France., Piulats JM; Catalan Institute of Oncology, Barcelona, Spain., Emmenegger U; Division of Medical Oncology, Odette Cancer Centre, Toronto, Canada., Shore ND; Carolina Urologic Research Center, Myrtle Beach, SC, USA., Romano E; Department of Oncology, Center for Cancer Immunotherapy, Institut Curie, Paris, France., Mourey L; Department of Medical Oncology, Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France., Li XT; MSD China, Beijing, China., Poehlein CH; Merck & Co., Inc., Rahway, NJ, USA., Schloss C; Merck & Co., Inc., Rahway, NJ, USA., Appleman LJ; UPMC Hillman Cancer Center, Pittsburgh, PA, USA., de Bono JS; The Institute of Cancer Research, The Royal Marsden Hospital, London, UK.

المصدر: European urology oncology [Eur Urol Oncol] 2024 Jun; Vol. 7 (3), pp. 509-518. Date of Electronic Publication: 2023 Nov 07.

نوع المنشور: Journal Article; Clinical Trial, Phase I; Clinical Trial, Phase II; Multicenter Study

بيانات الدورية: Publisher: Elsevier B.V Country of Publication: Netherlands NLM ID: 101724904 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2588-9311 (Electronic) Linking ISSN: 25889311 NLM ISO Abbreviation: Eur Urol Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Benzamides*/therapeutic use , Phenylthiohydantoin*/therapeutic use , Prostatic Neoplasms, Castration-Resistant*/drug therapy , Prostatic Neoplasms, Castration-Resistant*/pathology , Prostatic Neoplasms, Castration-Resistant*/mortality , Nitriles*/therapeutic use , Antibodies, Monoclonal, Humanized*/therapeutic use , Antibodies, Monoclonal, Humanized*/adverse effects , Abiraterone Acetate*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use, Humans ; Male ; Aged ; Middle Aged ; Aged, 80 and over ; Cohort Studies ; Neoplasm Metastasis

المؤلفون: Heiss BL; Center for Drug Evaluation and Research (CDER), US Food and Drug Administration, Silver Spring, MD., Chang E; Center for Drug Evaluation and Research (CDER), US Food and Drug Administration, Silver Spring, MD., Gao X; Center for Drug Evaluation and Research (CDER), US Food and Drug Administration, Silver Spring, MD., Truong T; Center for Drug Evaluation and Research (CDER), US Food and Drug Administration, Silver Spring, MD., Brave MH; Center for Drug Evaluation and Research (CDER), US Food and Drug Administration, Silver Spring, MD., Bloomquist E; Merck & Co, Rahway, NJ., Shah A; Center for Drug Evaluation and Research (CDER), US Food and Drug Administration, Silver Spring, MD., Hamed S; Astellas Pharma, Tokyo, Japan., Kraft J; Center for Drug Evaluation and Research (CDER), US Food and Drug Administration, Silver Spring, MD., Chiu HJ; Center for Drug Evaluation and Research (CDER), US Food and Drug Administration, Silver Spring, MD., Ricks TK; Center for Drug Evaluation and Research (CDER), US Food and Drug Administration, Silver Spring, MD., Tilley A; Center for Drug Evaluation and Research (CDER), US Food and Drug Administration, Silver Spring, MD., Pierce WF; Center for Drug Evaluation and Research (CDER), US Food and Drug Administration, Silver Spring, MD., Tang L; Center for Devices and Radiological Health (CDRH), US Food and Drug Administration, Silver Spring, MD., Abukhdeir A; AstraZeneca, Cambridge, United Kingdom., Kalavar S; Center for Devices and Radiological Health (CDRH), US Food and Drug Administration, Silver Spring, MD., Philip R; Oncology Center of Excellence (OCE), US Food and Drug Administration, Silver Spring, MD., Tang S; Center for Drug Evaluation and Research (CDER), US Food and Drug Administration, Silver Spring, MD., Pazdur R; Oncology Center of Excellence (OCE), US Food and Drug Administration, Silver Spring, MD., Amiri-Kordestani L; Center for Drug Evaluation and Research (CDER), US Food and Drug Administration, Silver Spring, MD., Kluetz PG; Oncology Center of Excellence (OCE), US Food and Drug Administration, Silver Spring, MD., Suzman DL; Center for Drug Evaluation and Research (CDER), US Food and Drug Administration, Silver Spring, MD.

المصدر: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2024 May 20; Vol. 42 (15), pp. 1851-1860. Date of Electronic Publication: 2024 Mar 07.

نوع المنشور: Journal Article; Randomized Controlled Trial

بيانات الدورية: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Prostatic Neoplasms, Castration-Resistant*/drug therapy , Prostatic Neoplasms, Castration-Resistant*/genetics , Prostatic Neoplasms, Castration-Resistant*/pathology , Nitriles*/therapeutic use , Phenylthiohydantoin*/therapeutic use , Phenylthiohydantoin*/analogs & derivatives , Benzamides*/therapeutic use , Phthalazines*/therapeutic use , Phthalazines*/administration & dosage , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , United States Food and Drug Administration* , Mutation* , Drug Approval* , Recombinational DNA Repair*, Humans ; Male ; United States ; Aged ; Double-Blind Method ; Middle Aged ; Aged, 80 and over ; Progression-Free Survival

المؤلفون: McKay RR; Moores Cancer Center, University of California San Diego, 3855 Health Sciences Drive, La Jolla, CA 92037, USA. Electronic address: rmckay@health.ucsd.edu., Morgans AK; Harvard Medical School, Dana-Farber Cancer Institute, 450 Brookline Ave, Dana 09-930, Boston, MA 02215, USA. Electronic address: aliciak_morgans@dfci.harvard.edu., Shore ND; Carolina Urologic Research Center, 823 82nd Parkway, Suite B, Myrtle Beach, SC 29572, USA. Electronic address: nshore@gsuro.com., Dunshee C; Urology Specialists, 2260 W. Orange Grove Road, Tucson, AZ 85741, USA. Electronic address: cdunshee@arizonauro.com., Devgan G; Pfizer Inc., 66 Hudson Blvd East, New York, NY 10001, USA. Electronic address: geeta.devgan@pfizer.com., Agarwal N; Huntsman Cancer Institute (NCI-CCC), University of Utah, 2000 Circle of Hope Drive, Suite 5726, Salt Lake City, UT 84112, USA. Electronic address: neeraj.agarwal@hci.utah.edu.

المصدر: Cancer treatment reviews [Cancer Treat Rev] 2024 May; Vol. 126, pp. 102726. Date of Electronic Publication: 2024 Mar 29.

نوع المنشور: Journal Article; Review

بيانات الدورية: Publisher: Elsevier Country of Publication: Netherlands NLM ID: 7502030 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-1967 (Electronic) Linking ISSN: 03057372 NLM ISO Abbreviation: Cancer Treat Rev Subsets: MEDLINE

مواضيع طبية MeSH: Poly(ADP-ribose) Polymerase Inhibitors*/therapeutic use , Prostatic Neoplasms, Castration-Resistant*/drug therapy , Prostatic Neoplasms, Castration-Resistant*/pathology , Prostatic Neoplasms, Castration-Resistant*/genetics , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Androgen Receptor Antagonists*/therapeutic use , Nitriles*/therapeutic use , Piperazines*/therapeutic use , Piperazines*/administration & dosage, Humans ; Male ; Phthalazines/therapeutic use ; Phenylthiohydantoin/therapeutic use ; Phenylthiohydantoin/analogs & derivatives ; United States ; Receptors, Androgen/genetics ; Benzamides/therapeutic use ; Piperidines/therapeutic use ; Indazoles/therapeutic use ; Signal Transduction/drug effects ; Recombinational DNA Repair/drug effects

المؤلفون: Emmett L; Department of Theranostics and Nuclear Medicine, St Vincent's Hospital, Sydney, NSW, Australia; St Vincent's Clinical School, University of New South Wales, Sydney, NSW, Australia; Garvan Institute of Medical Research, Sydney, NSW, Australia. Electronic address: louise.emmett@svha.org.au., Subramaniam S; NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia; Department of Medical Oncology, Bankstown-Lidcombe Hospital, Sydney, NSW, Australia., Crumbaker M; Department of Theranostics and Nuclear Medicine, St Vincent's Hospital, Sydney, NSW, Australia; Department of Medical Oncology, Kinghorn Cancer Centre, St Vincent's Hospital, Sydney, NSW, Australia; St Vincent's Clinical School, University of New South Wales, Sydney, NSW, Australia; Garvan Institute of Medical Research, Sydney, NSW, Australia; Macquarie University Hospital, Sydney, NSW, Australia., Nguyen A; Department of Theranostics and Nuclear Medicine, St Vincent's Hospital, Sydney, NSW, Australia; St Vincent's Clinical School, University of New South Wales, Sydney, NSW, Australia., Joshua AM; Department of Medical Oncology, Kinghorn Cancer Centre, St Vincent's Hospital, Sydney, NSW, Australia; Garvan Institute of Medical Research, Sydney, NSW, Australia., Weickhardt A; Olivia Newton-John Cancer and Wellness Centre, Austin Health, Melbourne, VIC, Australia; School of Cancer Medicine, La Trobe University, Melbourne, VIC, Australia., Lee ST; Department of Molecular Imaging and Therapy, Austin Health, Melbourne, VIC, Australia; School of Cancer Medicine, La Trobe University, Melbourne, VIC, Australia; Olivia Newton-John Cancer Research Institute, Melbourne, VIC, Australia; Department of Medicine and Department of Surgery, University of Melbourne, Melbourne, VIC, Australia., Ng S; Department of Oncology, Sir Charles Gairdner Hospital, Perth, WA, Australia; Department of Oncology, University of Western Australia, Perth, WA, Australia., Francis RJ; Department of Nuclear Medicine, Sir Charles Gairdner Hospital, Perth, WA, Australia; Medical School, University of Western Australia, Perth, WA, Australia., Goh JC; Department of Medical Oncology, Royal Brisbane and Women's Hospital, Brisbane, QLD, Australia; Queensland University of Technology, Brisbane, QLD, Australia., Pattison DA; Department of Nuclear Medicine and Specialised PET Services, Royal Brisbane and Women's Hospital, Brisbane, QLD, Australia; School of Medicine, University of Queensland, Brisbane, QLD, Australia., Tan TH; Department of Medical Oncology, Royal Adelaide Hospital, Adelaide, SA, Australia., Kirkwood ID; Nuclear Medicine, PET and Bone Densitometry, Royal Adelaide Hospital, Adelaide, SA, Australia; Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, SA, Australia., Gedye C; Department of Medical Oncology, Calvary Mater Newcastle, Waratah, NSW, Australia., Rutherford NK; Department of Nuclear Medicine, Hunter New England Health, Newcastle, NSW, Australia., Sandhu S; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia; Prostate Cancer Theranostics and Imaging Centre of Excellence (ProsTIC), Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia., Kumar AR; Prostate Cancer Theranostics and Imaging Centre of Excellence (ProsTIC), Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia., Pook D; Department of Oncology, Monash Health, Melbourne, VIC, Australia., Ramdave S; Monash Health Imaging, Monash Health, Melbourne, VIC, Australia., Nadebaum DP; Department of Oncology, Alfred Health, Melbourne, VIC, Australia., Voskoboynik M; Department of Oncology, Alfred Health, Melbourne, VIC, Australia; Central Clinical School, Monash University, Melbourne, VIC, Australia., Redfern AD; Medical School, University of Western Australia, Perth, WA, Australia; Department of Medical Oncology, Fiona Stanley Hospital, Perth, WA, Australia., Macdonald W; Medical School, University of Western Australia, Perth, WA, Australia; Department of Nuclear Medicine, Fiona Stanley Hospital, Perth, WA, Australia., Krieger L; Genesis Care North Shore, Sydney, NSW, Australia., Schembri G; Nuclear Medicine, Royal North Shore Hospital, Sydney, NSW, Australia., Chua W; Department of Medical Oncology, Liverpool Hospital, Sydney, NSW, Australia; Western Sydney University, Sydney, NSW, Australia., Lin P; South Western Sydney Clinical School, University of New South Wales, Sydney, NSW, Australia; Department of Nuclear Medicine and PET, Liverpool Hospital, Sydney, NSW, Australia., Horvath L; Department of Medical Oncology, Chris O'Brien Lifehouse, Sydney, NSW, Australia., Bastick P; Department of Medical Oncology, St George Hospital, Sydney, NSW, Australia., Butler P; Department of Nuclear Medicine, St George Hospital, Sydney, NSW, Australia., Zhang AY; NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia; Macquarie University Hospital, Sydney, NSW, Australia; Department of Medical Oncology, Chris O'Brien Lifehouse, Sydney, NSW, Australia., Yip S; NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia., Thomas H; NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia., Langford A; NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia., Hofman MS; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia; Prostate Cancer Theranostics and Imaging Centre of Excellence (ProsTIC), Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia., McJannett M; Australian and New Zealand Urogenital and Prostate Cancer Trials Group, Sydney, NSW, Australia., Martin AJ; NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia; Centre for Clinical Research, University of Queensland, Brisbane, QLD, Australia., Stockler MR; NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia; Department of Medical Oncology, Chris O'Brien Lifehouse, Sydney, NSW, Australia., Davis ID; Monash University Eastern Health Clinical School, Melbourne, VIC, Australia; Eastern Health, Melbourne, VIC, Australia.

مؤلفون مشاركون: ENZA-p Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group

المصدر: The Lancet. Oncology [Lancet Oncol] 2024 May; Vol. 25 (5), pp. 563-571. Date of Electronic Publication: 2024 Apr 12.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't; Randomized Controlled Trial; Multicenter Study; Clinical Trial, Phase II

بيانات الدورية: Publisher: Lancet Pub. Group Country of Publication: England NLM ID: 100957246 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-5488 (Electronic) Linking ISSN: 14702045 NLM ISO Abbreviation: Lancet Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Prostatic Neoplasms, Castration-Resistant*/drug therapy , Prostatic Neoplasms, Castration-Resistant*/pathology , Prostatic Neoplasms, Castration-Resistant*/mortality , Phenylthiohydantoin*/administration & dosage , Phenylthiohydantoin*/therapeutic use , Phenylthiohydantoin*/analogs & derivatives , Benzamides* , Nitriles* , Lutetium* , Dipeptides*/therapeutic use , Dipeptides*/administration & dosage , Dipeptides*/adverse effects , Heterocyclic Compounds, 1-Ring*/therapeutic use , Heterocyclic Compounds, 1-Ring*/administration & dosage , Heterocyclic Compounds, 1-Ring*/adverse effects , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use, Humans ; Male ; Aged ; Middle Aged ; Prostate-Specific Antigen/blood ; Progression-Free Survival ; Radioisotopes/therapeutic use ; Aged, 80 and over ; Radiopharmaceuticals

المؤلفون: Saad F; Centre Hospitalier de l'Université de Montréal, Montreal, Canada. Electronic address: fred.saad@umontreal.ca., Clarke NW; The Christie and Salford Royal Hospital NHS Foundation Trusts and University of Manchester, Manchester, UK. Electronic address: noel.clarke@nca.nhs.uk., Oya M; Keio University School of Medicine, Tokyo, Japan., Shore N; Carolina Urologic Research Center, Myrtle Beach, SC, USA., Procopio G; Programma Prostata Fondazione Istituto Nazionale Tumori Milano, Milan, Italy., Guedes JD; Hospital de Base de São José do Rio Preto, São José do Rio Preto, Brazil., Arslan C; Izmir Economy University Medical Point Hospital, Karsiyaka, Izmir, Turkey., Mehra N; Radboud Universitair Medisch Centrum, Nijmegen, Netherlands., Parnis F; Ashford Cancer Centre Research, Adelaide, Australia., Brown E; University Hospital Southampton, Southampton, UK., Schlürmann F; CHI de Cornouaille, Quimper, France., Joung JY; National Cancer Center, Goyang, South Korea., Sugimoto M; Kagawa University Hospital, Kagawa, Japan., Sartor O; Mayo Clinic, Rochester, MN, USA., Liu YZ; Precision Medicine, Oncology R&D, AstraZeneca, Cambridge, UK., Poehlein C; Merck & Co, Rahway, NJ, USA., Barker L; Global Medicines Development, Oncology R&D, AstraZeneca, Cambridge, UK., Del Rosario PM; Global Medicines Development, Oncology R&D, AstraZeneca, Cambridge, UK., Armstrong AJ; Duke Cancer Institute Center for Prostate and Urologic Cancer, Duke University, Durham, NC, USA.

المصدر: The Lancet. Oncology [Lancet Oncol] 2023 Oct; Vol. 24 (10), pp. 1094-1108. Date of Electronic Publication: 2023 Sep 12.

نوع المنشور: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Clinical Trial, Phase III; Multicenter Study

بيانات الدورية: Publisher: Lancet Pub. Group Country of Publication: England NLM ID: 100957246 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-5488 (Electronic) Linking ISSN: 14702045 NLM ISO Abbreviation: Lancet Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Prostatic Neoplasms, Castration-Resistant*/drug therapy , Prostatic Neoplasms, Castration-Resistant*/pathology , Prostatic Neoplasms, Castration-Resistant*/mortality , Phthalazines*/therapeutic use , Phthalazines*/adverse effects , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/adverse effects , Piperazines*/therapeutic use , Piperazines*/adverse effects , Androstenes*/therapeutic use , Androstenes*/adverse effects, Humans ; Male ; Double-Blind Method ; Aged ; Middle Aged ; Progression-Free Survival ; Aged, 80 and over ; Neoplasm Metastasis

المؤلفون: Merseburger AS; Department of Urology, Universitätsklinikum Schleswig-Holstein, Lübeck, Germany. Electronic address: axel.merseburger@uksh.de., Attard G; Department of Oncology, University College London Cancer Institute, London, UK., Åström L; Department of Immunology, Genetics and Pathology, University of Uppsala, Uppsala, Sweden., Matveev VB; Department of Urology, Blokhin Cancer Research Center, Moscow, Russia., Bracarda S; Medical Oncology, Azienda Ospedaliera Santa Maria, Terni, Italy., Esen A; Department of Urology, Dokuz Eylul University, Konak, Türkiye., Feyerabend S; Studienpraxis Urologie, Nürtingen, Germany., Senkus E; Department of Oncology and Radiotherapy, Medical University of Gdańsk, Gdańsk, Poland., López-Brea Piqueras M; Department of Medical Oncology, Marqués de Valdecilla University Hospital, Cantabria, Spain., Boysen G; Medical Affairs, Astellas Pharma Europe, Addlestone, UK., Gourgioti G; Medical Affairs, Astellas Pharma Europe, Addlestone, UK., Martins K; Medical Affairs, Astellas Pharma Europe, Addlestone, UK., Chowdhury S; Medical Oncology, Guy's and St Thomas' NHS Foundation Trust, King's College London, London, UK.

المصدر: The Lancet. Oncology [Lancet Oncol] 2022 Nov; Vol. 23 (11), pp. 1398-1408. Date of Electronic Publication: 2022 Oct 18.

نوع المنشور: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Lancet Pub. Group Country of Publication: England NLM ID: 100957246 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-5488 (Electronic) Linking ISSN: 14702045 NLM ISO Abbreviation: Lancet Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Combined Chemotherapy Protocols*/adverse effects , Prostatic Neoplasms, Castration-Resistant*/drug therapy , Prostatic Neoplasms, Castration-Resistant*/pathology, Humans ; Male ; Androgen Antagonists/therapeutic use ; Docetaxel/therapeutic use ; Double-Blind Method ; Neutropenia/epidemiology ; Prednisolone/therapeutic use ; Prostate-Specific Antigen ; Treatment Outcome